
In the second part of a two-part interview, Paz Vellanki of Precision for Medicine explains which confirmatory evidence can support a single-trial approval and why she expects FDA's rare disease framework to last.
• Background on capillary electrophoresis • Importance of glycan screening • Benefits of high-throughput screening with intuitive data analysis







